Shanghai Handsome Biotech

Shanghai Handsome Biotech, a subsidiary of the Handsome Investment Group (also known as Hansen Group), is a biotechnology company based in China that focuses on the development and production of diagnostic products and cosmeceuticals. The company is particularly recognized for its work in infectious diseases, specifically developing diagnostic drugs for tuberculosis (TB). Beyond its own product development, Shanghai Handsome Biotech operates as a service provider, offering primer synthesis and DNA sequencing to the scientific community. The company has also expanded its reach into the cosmeceutical market through the acquisition of Guangzhou Qi Bao Biotechnology, utilizing its biotechnology platform to develop advanced skin care products. Historically, the company played a significant role in the biopharmaceutical sector as a key shareholder in Shanghai Qiaer Bio-Technology, the developer of the cancer therapy rh-Apo2l.